Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Six: Lawmakers Who Will Stand Behind Public Plan To The End

This article was originally published in RPM Report

Executive Summary

The public plan has turned into the legislative fault line between Democrats and Republicans when it comes to health reform. The key question is not who is most vocal in advocating the plan, but rather who is most able to stand up for it in the legislative process.

You may also be interested in...



Health Care Reform: Plan for Quick Action Dashed By Daschle Withdrawal

The withdrawal of Tom Daschle from consideration as HHS Secretary means there won't be a single focus for health care policy during the upcoming health care reform debate. Can two powerful Democratic legislators and the Obama budget team fill the void?

Health Care and the 2008 Election: Revolution, Reform or Return to Business-as-Usual?

As the presidential race heats up, health care executives say they have many reasons to be excited–and nervous. Boston Consulting Group reviews an industry-wide survey on the implications of the candidates’ health care proposals for the pharma and device industries.

Accelerated Approval For Gene Therapies: FDA’s Wilson Bryan Offers A ‘Framework’

Bryan, who oversees reviews of gene and cell therapies in US FDA’s biologics center, cautioned against falling in love with a biomarker when it is showing no ‘clinical effect.’

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel